UNSPSC 51431601: Anipamil

This classification denotes a calcium channel blocker, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9Y54WZV1CJ. European Medicines Agency schedules Anipamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05516MIG. Anipamil generally arises in the molecular formula C34H52N2O2.

UNSPSC 51431601 Anipamil is a Commodity code that encompasses branded and generic cardiovascular and emergency medications supplied to state and local health agencies, fire departments, and cooperative purchasing alliances. State and local governments buy specific pharmaceutical products under this code for emergency medical services, hospital formularies, and multi-state pharmacy benefit programs, with vendors required to meet FDA compliance, expiration-date minimums, and supply-chain security standards. Issuing bodies include city fire and rescue departments, state health and human services commissions, and cooperative purchasing organizations spanning multiple states. The City of Tampa Fire Rescue, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the mix of local, state, and regional buying entities procuring under this code.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) on April 24, 2026, with a response deadline of April 8, 2026, for Tampa Fire Rescue use in Hillsborough County at an estimated contract value of $40,000 and a one-year term with renewal options. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—a market-intelligence phase preceding formal competitive solicitation. The Minnesota Department of Administration's MMCAP office issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local facilities in Minnesota and Oregon, with award effective July 1, 2026. The Tampa solicitation includes a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. Vendors must provide Safety Data Sheets compliant with OSHA standards and demonstrate expiration-date maintenance of nine months or longer from acceptance.